NCT07336927

IAT-MeVO Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial

Efficacy and Safety of Endovascular Therapy With Intra-Arterial Thrombolysis for Medium Vessel Occlusion Stroke--the IAT-MeVO Trial

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 614 (estimated)
• Sponsor: Bo Wu · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

IAT-MeVO is an international, multicenter, prospective, randomised, open-label, blinded end-point assessed (PROBE) trial, to evaluate the efficacy and safety of endovascular therapy (EVT) \[intra-arterial thrombolysis (IAT)-based\] versus best medical management (BMT) in patients with acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) who are ineligible for intravenous thrombolysis (IV) within 24 h of onset.

Conditions

• Acute Ischemic Stroke Due to Medium-vessel-occlusion

Interventions

Type	Name	Description
PROCEDURE	Endovascular Treatment	Patients will receive IAT-based EVT in addition to medical treatment. IAT with TNK will be performed first. If adequate dosing fails to achieve reperfusion, the surgical team may evaluate the need for aspiration or stent retriever thrombectomy. For second-order branches (M2/A1/P1 segments), the number of retrieval attempts must not exceed three; for third-order branches (M3/A2/P2 and beyond), no more than two attempts are allowed. \*Arterial thrombolysis protocol: Dose: 0.125 mg/kg body weight, maximum 12.5 mg \*No restrictions will be placed on the choice of aspiration catheters or stent retrievers used in this study.

Timeline

• Start date: 2026-01-01
• Primary completion: 2030-12-31
• Completion: 2030-12-31
• First posted: 2026-01-13
• Last updated: 2026-01-15

Locations

1 site across 1 country: China